Literature DB >> 11313814

Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen.

K F Hsu1, C F Hung, W F Cheng, L He, L A Slater, M Ling, T C Wu.   

Abstract

Naked DNA vaccines represent an attractive approach for generating antigen-specific immunity because of their stability and simplicity of delivery. There are particular concerns with DNA vaccines however, such as potential integration into the host genome, cell transformation, and limited potency. The usage of DNA-based alphaviral RNA replicons (suicidal DNA vectors) may alleviate the concerns of integration or transformation since suicidal DNA vectors eventually cause lysis of transfected cells. To improve further the potency of suicidal DNA vaccines, we evaluated the effect of linking Mycobacterium tuberculosis heat shock protein 70 (Hsp70) to human papillomavirus type 16 (HPV-16) E7 as a model antigen on antigen-specific immunity generated by a DNA-based Semliki Forest virus (SFV) RNA vector, pSCA1. Our results indicated that this suicidal DNA vaccine containing E7/Hsp70 fusion genes generated significantly higher E7-specific T cell-mediated immune responses than vaccines containing the wild-type E7 gene in vaccinated mice. More importantly, this fusion converted a less effective vaccine into one with significant potency against established E7-expressing metastatic tumors. The antitumor effect was predominantly CD8-dependent. These results indicate that linkage of Hsp70 to the antigen may greatly enhance the potency of suicidal DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313814     DOI: 10.1038/sj.gt.3301408

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  25 in total

Review 1.  Current state in the development of candidate therapeutic HPV vaccines.

Authors:  Andrew Yang; Jessica Jeang; Kevin Cheng; Ting Cheng; Benjamin Yang; T-C Wu; Chien-Fu Hung
Journal:  Expert Rev Vaccines       Date:  2016-03-07       Impact factor: 5.217

2.  [Diagnostic and prognostic biomarkers in head and neck squamous cell carcinoma].

Authors:  G Lehnerdt; T K Hoffmann; S Mattheis; S Brandau; R Zeidler; S Lang
Journal:  HNO       Date:  2010-07       Impact factor: 1.284

3.  The preparation of HL-60 cells vaccine expressing BCG heat shock protein 70 and detection of its immunogenicity in vitro.

Authors:  Xiao-Ling Li; Yan-Xia Zhao; Li-Rong Sun; Jing Yang; Hui-Juan Xu
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

Review 4.  DNA vaccines for HIV: challenges and opportunities.

Authors:  David A Hokey; David B Weiner
Journal:  Springer Semin Immunopathol       Date:  2006-10-10

5.  N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.

Authors:  Nafiseh Pakravan; Sara Soudi; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2010-03-12       Impact factor: 3.667

Review 6.  Clinical implications of human papillomavirus in head and neck cancers.

Authors:  Carole Fakhry; Maura L Gillison
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

Review 7.  Cervical cancer screening.

Authors:  Dorothy J Wiley; Bradley J Monk; Emmanuel Masongsong; Kristina Morgan
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

8.  A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity.

Authors:  Lifeng Wang; Lisa Rollins; Qinlong Gu; Si-Yi Chen; Xue F Huang
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641

Review 9.  Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Authors:  Chien-Fu Hung; Barbara Ma; Archana Monie; Shaw-Wei Tsen; T-C Wu
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

10.  Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A.

Authors:  Joanna R Kirman; Tara Turon; Hua Su; Amy Li; Carl Kraus; John M Polo; John Belisle; Sheldon Morris; Robert A Seder
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.